Expression of BRCA1-IRIS in breast tumor samples.

<p>(A) DAPI stained HME cells transfected with Myc-tagged BRCA1-IRIS cDNA. Same cell stained with anti-Myc (red, B), anti-BRCA1-IRIS (green, C). (D) Merge of B and C. (E) Expression of BRCA1-IRIS in HME or BRCA1-IRIS overexpressing cells (IRIS) following transfection of luciferase or BRCA1-IRIS siRNA. (F and G) are low and high magnification images of invasive breast cancer section stained with pre-absorbed anti-BRCA1-IRIS antibody. Expression of BRCA1-IRIS in paraffin embedded normal mammary epithelial tissue (H and I), DCIS (J and K) or invasive breast cancer tissues (L and M). H, J and L are low magnification images, whereas I, K and M are high magnification images. Note the BRCA1-IRIS-psoitive (solid arrow) and -negative (dashed arrow) cells in K. Also note that while all sections are counter stained with hematoxylin, for technical reasons, the staining was done for shorter time in J, K, L and M compared to F, G, H and I. (N) Expression of 18S and BRCA1-IRIS mRNA (in duplicates) in 5 normal (N) and 19 breast tumors (T). Bars are, 400 µm in H, J, 200 µm in F, K and L, 100 µm in I and M and 50 µm in G.</p

Relationships between BRCA1-IRIS level and marker expression and tumor characteristics in Her2⁺ and TN/BL breast cancer tumor samples.

a<p>Spearman rank coefficient test correlation (r),</p>b<p>Spearman rank coefficient test <i>p</i>-value,</p>c<p>To compare multiple groups with one control group, analysis of variance (ANOVA) was used.</p><p><i>p</i>-values (two-sided) <0.05 were considered statistically significant.</p

Expression of BRCA1-IRIS, AKT1, AKT2, p-AKT, survivin and BRCA/p220 in breast tumors.

<p>Representative sections of TN/BL breast tumor tissues showing low (A, B, C, G, H, and I) and high (D, E, F, J, K, and L) magnification images of sections stained for BRCA1-IRIS (A and D), AKT1 (B and E), AKT2 (C and F), p-AKT (D and J), survivin (H and K), and BRCA1/p220 (I and L). Bars are 400 µm in A–D and 200 µm in E–H.</p

Immunohistochemical and pathologic characteristics significantly different in LT/Ras^V12<i>vs.</i> LT/IRIS subcutaneous tumors.

<p>Immunohistochemical and pathologic characteristics significantly different in LT/Ras^V12<i>vs.</i> LT/IRIS subcutaneous tumors.</p

The association between BRCA1-IRIS overexpression and overexpression/activation of AKT and survivin in breast tumors.

<p>a is Fisher's exact <i>p</i>-value.</p

Immunohistochemical analysis of Ras^V12 or BRCA1-IRIS-induced subcutaneous tumors.

<p>Representative high magnification sections from tumor xenografts developed in mice injected with HME cells expression TERT/LT/Ras^V12 (A, C, E, G and I) or TERT/LT/IRIS (B, D, F, H and J) stained for BRCA1-IRIS (A and B), AKT1 (C and D), AKT2 (E and F), p-AKT (G and H) and survivin (I and J). Bar is 200 µm.</p

Correlations between BRCA1-IRIS expression and AKT1, AKT2, p-AKT and survivin in breast tumor samples.

<p>Nonparametric <i>Spearman rank correlation test</i> comparing BRCA-IRIS and AKT1, AKT2, p-AKT, and survivin on 326 breast tumors TMAs. The staining for each marker was scored as described in the text and the results were blotted. Insets show Spearman correlation coefficient (r) and <i>p</i>-value for each correlation.</p

BRCA1-IRIS mRNA expression in NMU-induced primary and invasive breast tumors.

<p>(A) RT/PCR analysis of rat <i>BRCA1-IRIS</i> mRNA expression in normal adult rat tissues (left) and several adult rat mammary glands (right). (B) RT/PCR analysis of the expression of <i>ERα</i> and <i>BRCA1-IRIS</i> mRNAs in several primary rat breast tumors generated flowing NMU treatment (P1–P8). (C) RT/PCR analysis of the expression of <i>ERα</i> and <i>BRCA1-IRIS</i> mRNAs in normal gland (N), three primary tumors P2, P4 and P6 and the first (2Ii, 4Ii and 6Ii) or the fourth (2Iiv, 4Iiv and 6Iiv) invasive tumors generated following serial transplantation of the mentioned primary tumors.</p